MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e740e1bfe9248e3844839c81b27bd6d
record_format dspace
spelling oai:doaj.org-article:7e740e1bfe9248e3844839c81b27bd6d2021-11-18T11:09:06ZMG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants1664-322410.3389/fimmu.2021.778829https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.778829/fullhttps://doaj.org/toc/1664-3224Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.Sua LeeShina JangJihoon KangSoo Bin ParkYoung Woo HanHyemi NamMunkyung KimJeewon LeeKi Joon ChoJeonghun KimMiyoung OhJihye RyuJong Hyeon SeokYunhwa KimJee-Boong LeeMan-Seong ParkYong-Sung KimHosun ParkDong-Sik KimDong-Sik KimFrontiers Media S.A.articleMG1141ASARS-CoV-2monoclonal antibodyoutbreakspike proteinImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic MG1141A
SARS-CoV-2
monoclonal antibody
outbreak
spike protein
Immunologic diseases. Allergy
RC581-607
spellingShingle MG1141A
SARS-CoV-2
monoclonal antibody
outbreak
spike protein
Immunologic diseases. Allergy
RC581-607
Sua Lee
Shina Jang
Jihoon Kang
Soo Bin Park
Young Woo Han
Hyemi Nam
Munkyung Kim
Jeewon Lee
Ki Joon Cho
Jeonghun Kim
Miyoung Oh
Jihye Ryu
Jong Hyeon Seok
Yunhwa Kim
Jee-Boong Lee
Man-Seong Park
Yong-Sung Kim
Hosun Park
Dong-Sik Kim
Dong-Sik Kim
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
description Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.
format article
author Sua Lee
Shina Jang
Jihoon Kang
Soo Bin Park
Young Woo Han
Hyemi Nam
Munkyung Kim
Jeewon Lee
Ki Joon Cho
Jeonghun Kim
Miyoung Oh
Jihye Ryu
Jong Hyeon Seok
Yunhwa Kim
Jee-Boong Lee
Man-Seong Park
Yong-Sung Kim
Hosun Park
Dong-Sik Kim
Dong-Sik Kim
author_facet Sua Lee
Shina Jang
Jihoon Kang
Soo Bin Park
Young Woo Han
Hyemi Nam
Munkyung Kim
Jeewon Lee
Ki Joon Cho
Jeonghun Kim
Miyoung Oh
Jihye Ryu
Jong Hyeon Seok
Yunhwa Kim
Jee-Boong Lee
Man-Seong Park
Yong-Sung Kim
Hosun Park
Dong-Sik Kim
Dong-Sik Kim
author_sort Sua Lee
title MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
title_short MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
title_full MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
title_fullStr MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
title_full_unstemmed MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
title_sort mg1141a as a highly potent monoclonal neutralizing antibody against sars-cov-2 variants
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d
work_keys_str_mv AT sualee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT shinajang mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jihoonkang mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT soobinpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT youngwoohan mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT hyeminam mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT munkyungkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jeewonlee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT kijooncho mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jeonghunkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT miyoungoh mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jihyeryu mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jonghyeonseok mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT yunhwakim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT jeeboonglee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT manseongpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT yongsungkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT hosunpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT dongsikkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
AT dongsikkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants
_version_ 1718420855123345408